Category

Insights
Medlior Publications

Medlior Publications

Explore a list of all of Medlior's recent publications including recent Medlior evidence generation publications and recent Medlior RWE publications. Recent Medlior RWE publications K. Larkin-Kaiser, C. Waters-Banker, T. Cowling, L.A. Snow I., Hasani M., Fernet....

Case Study: Atherosclerotic Cardiovascular Disease

Case Study: Atherosclerotic Cardiovascular Disease

Medlior’s RWE study examining the treatment landscape and clinical outcomes for patients with atherosclerotic cardiovascular disease in Alberta Introduction Medlior Health Outcomes Research Ltd. was engaged by Amgen Inc., one of the world’s leading biopharmaceutical...

EAHAD 2020: Haemophilia-A SLR Project

EAHAD 2020: Haemophilia-A SLR Project

Haemophilia-A (HA) is a congenital x‐linked bleeding disorder caused by a deficiency of blood coagulation factor VIII (FVIII), occurring in approximately one in every 5000 male live births. HA is currently without a cure and therefore requires life-long monitoring and treatment of potentially life‐threatening bleeding events. Existing treatments for the management of this disorder include the use of plasma‐derived factor concentrates, recombinant factor concentrates, and more recently, monoclonal antibodies (e.g. emicizumab).

DLBCL Environmental Scan

DLBCL Environmental Scan

Understanding and identifying the unmet need of aggressive B-cell lymphomas is critical for positioning new therapies Aggressive B-cell lymphomas are a subset of non-Hodgkin’s lymphoma (NHL) that encompass a number of neoplasms that include both precursor lymphoid...